Replies to post #118048 on Biotech Values

[DewDiligence]

Branded Generics in Emerging Markets—Connecting the Dots

MRK’s PR today on the deal with Sun Pharma (#msg-61940959) says the following:

…during the coming decade,…Emerging Markets are expected to drive 90% of the world's pharmaceutical growth, with 75% of that growth coming from branded generics.

By simple arithmetic, this means that 2/3 of the overall growth in the global pharmaceutical industry will come from branded generics in emerging markets. Hence, the reason I’ve been posting ad nauseam that branded generics in emerging markets are the big Big Pharma story that many investors and analysts have been overlooking.

[trade2much]

DewDiligence: are there any less expensive biotechs in this arena which you like?

TIA